Screening and enrollment of patients is on-going at all active trial sites. 58 patients have now been enrolled into the study. More than half the enrolled patients have completed the dosing phase of the trial. The study continues under the supervision of a Data and Safety Monitoring Board - an independent group of neuroscience experts who oversee a strict safety protocol for the conduct of the trial. While the company correctly anticipated the timeframe for trial approval in Russia, various administrative processes in Russia have delayed the initiation of the clinical trial at the Russian sites thus impacting on the projected timeline for completion of the trial. The company now expects that all the remaining patients will be enrolled and the study completed in time for trial results to be reported in 1Q'08, which is slightly later than previous guidance of year end '07.

More information about ANP.AX

http://au.biz.yahoo.com/070912/38/1e7i2.html